A Study of Regorafenib in Advanced Pancreatic Cancer Patients

NCT02080260 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: regorafenib

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]